X-Cell Says Estradiol May Offer Greater Restenotic Benefit
This article was originally published in The Pink Sheet Daily
Executive Summary
Estrogen-based anti-restenotic drug could accelerate healing and have lower rates of stent thrombosis than J&J's Cypher and Boston Scientific's Taxus, according to the firm.